Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

784 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM).
González A, Lluch A, Aba E, Albanell J, Antón A, Álvarez I, Ayala F, Barnadas A, Calvo L, Ciruelos E, Cortés J, de la Haba J, López-Vega JM, Martínez E, Muñoz M, Peláez I, Redondo A, Rodríguez Á, Rodríguez CA, Ruíz A, Llombart A. González A, et al. Among authors: anton a. Clin Transl Oncol. 2017 May;19(5):616-624. doi: 10.1007/s12094-016-1571-4. Epub 2016 Nov 16. Clin Transl Oncol. 2017. PMID: 27853985 Review.
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Antón A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J. Tabernero J, et al. Among authors: anton a. Ann Oncol. 2004 Sep;15(9):1358-65. doi: 10.1093/annonc/mdh349. Ann Oncol. 2004. PMID: 15319242 Free article. Clinical Trial.
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Martín M, Lluch A, Seguí MA, Ruiz A, Ramos M, Adrover E, Rodríguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacón C, Roset M, Antón A, Isla D, del Prado PM, Iglesias L, Zaluski J, Arcusa A, López-Vega JM, Muñoz M, Mel JR. Martín M, et al. Among authors: anton a. Ann Oncol. 2006 Aug;17(8):1205-12. doi: 10.1093/annonc/mdl135. Epub 2006 Jun 9. Ann Oncol. 2006. PMID: 16766587 Free article. Clinical Trial.
Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.
Antón A, Ruiz A, Seguí MA, Calvo L, Muñoz M, Lao J, Sancho F, Fernández L. Antón A, et al. Ann Oncol. 2009 Mar;20(3):454-9. doi: 10.1093/annonc/mdn663. Epub 2008 Dec 11. Ann Oncol. 2009. PMID: 19074216 Free article. Clinical Trial.
Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.
Antón A, Ruiz A, Plazaola A, Calvo L, Seguí MA, Santaballa A, Muñoz M, Sánchez P, Miguel A, Carrasco E, Lao J, Camps J, Alfaro J, Antolín S, Cámara MC. Antón A, et al. Ann Oncol. 2011 Jan;22(1):74-79. doi: 10.1093/annonc/mdq317. Epub 2010 Jul 5. Ann Oncol. 2011. PMID: 20603435 Free article. Clinical Trial.
Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).
Pazo-Cid RA, Lanzuela M, Esquerdo G, Pérez-Gracia JL, Antón A, Amigo G, Trufero JM, García-Otín AL, Martín-Duque P. Pazo-Cid RA, et al. Among authors: anton a. Clin Transl Oncol. 2012 Aug;14(8):564-74. doi: 10.1007/s12094-012-0842-y. Epub 2012 Jul 18. Clin Transl Oncol. 2012. PMID: 22855137
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study.
Alba E, Chacon JI, Lluch A, Anton A, Estevez L, Cirauqui B, Carrasco E, Calvo L, Segui MA, Ribelles N, Alvarez R, Sanchez-Muñoz A, Sanchez R, Garcia-Asenjo JA, Rodriguez-Martin C, Escudero MJ, Albanell J. Alba E, et al. Among authors: anton a. Breast Cancer Res Treat. 2012 Nov;136(2):487-93. doi: 10.1007/s10549-012-2100-y. Epub 2012 Oct 9. Breast Cancer Res Treat. 2012. PMID: 23053638 Clinical Trial.
784 results